Nebenwirkungen · Lynparza
Lynparza 100 mg film-coated tablets Lynparza 150 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-130522 · Präparat HOS-096931
When used in combination with durvalumab following treatment with durvalumab in combination with platinum-based chemotherapy, adverse events led to dose interruption and/or reduction of olaparib in 59.9% of patients and led to permanent discontinuation of treatment with olaparib in 10.9% of patients. The adverse reactions that most commonly led to dose interruption and/or reduction of olaparib were anaemia (20.8%), nausea (8.3%), neutropenia (7.3%), fatigue/asthenia (5.7%), thrombocytopenia (4.2%), vomiting (4.2%), blood creatinine increased (3.1%), leukopenia (3.1%), and decreased appetitive (2.6%), diarrhoea (2.1%). The adverse reactions that most commonly led to permanent discontinuation of olaparib were anaemia (3.6%) and neutropenia (1%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-19T16:20:00Z · SHA-256 04cb6a8e4fff66099a345e60858378068000de050b0e7fedaddb3d5347849598 · Passage d7d73b3d33bbc39f88f6160f5caead6ef6c209f2cae56f08d09ee9b08991fbcb · Zeichen 2732–3485 im Abschnitt